Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q15386
UPID:
UBE3C_HUMAN
Alternative names:
HECT-type ubiquitin transferase E3C; Homologous to E6AP carboxyl terminus homologous protein 2; RTA-associated ubiquitin ligase
Alternative UPACC:
Q15386; A4D235; A6NCP3; Q8TC15; Q96CR4; Q9UDU3
Background:
Ubiquitin-protein ligase E3C, known for its roles in protein ubiquitination, catalyzes 'Lys-29'- and 'Lys-48'-linked polyubiquitin chains. It interacts with the proteasome to promote ubiquitin chain elongation on substrates, facilitating their degradation. This protein also regulates autophagy and type I interferon response through targeted ubiquitination, showcasing its pivotal role in cellular processes.
Therapeutic significance:
Understanding the role of Ubiquitin-protein ligase E3C could open doors to potential therapeutic strategies.